Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells

Pharmacology, Toxicology and Pharmaceutical Science

• 5 Chloro 4 [[2 (Isopropylsulfonyl)phenyl]amino] 2 [[2 Methoxy 4 [4 (4 Methyl 1 Piperazinyl) 1 Piperidinyl]phenyl]amino]pyrimidine 30%
• Anaplastic Lymphoma Kinase 100%
• Anaplastic Lymphoma Kinase Inhibitor 30%
• Antiapoptotic 10%
• Apoptosis 50%
• BIM Protein 10%
• Cell Proliferation 30%
• Combination Therapy 10%
• Drug 10%
• Echinoderm 70%
• Microtubule Associated Protein 70%
• Mitogen Activated Protein Kinase Kinase Inhibitor 30%
• Non Small Cell Lung Cancer 50%
• Protein 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Survivin 20%